In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Impact of significant mitral regurgitation on mortality in patients without ischemic cardiomyopathy treated with transfemoral TAVI

Session Poster Session 1

Speaker Alfredo Chauca Tapia

Congress : Acute Cardiovascular Care 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Interventional Cardiology - Other
  • Session type : Poster Session
  • FP Number : P284

Authors : A Chauca Tapia (Cadiz,ES), I Noval Morillas (Cadiz,ES), E Izaga Torralba (Cadiz,ES), F Garcias Lanzas (Cadiz,ES), A Gutierrez Barrios (Cadiz,ES), G Calle Perez (Cadiz,ES), R Vazquez Garcia (Cadiz,ES)

Authors:
A Chauca Tapia1 , I Noval Morillas1 , E Izaga Torralba1 , F Garcias Lanzas1 , A Gutierrez Barrios1 , G Calle Perez1 , R Vazquez Garcia1 , 1University Hospital Puerta del Mar, Cardiology - Cadiz - Spain ,

Citation:

Background:
The aim of this study is analyze the impact of significant mitral regurgitation (MR) in patients diagnosed of severe aortic stenosis wihout ischemic heart disease treated with transfemoral TAVI.
Methods and results:
This is a retrospecive study of patiens with severe aortic steneosis (AS) treated with transfemoral TAVI between 2011 and 2018 in tertiary hospital. Significant mitral regurgitation was defined as moderate or severe MR assessed by 2D transthoracic echocardiography.
From the patients that were included in our study, 54.8% (90/164) did not have ischemic heart disease and from this group 23.3% (21/90) had significant MR. The statistically significant differences between patiens with and without significant MR were left ventricular ejection fraction (LVEF) (53.05%vs60.6%;p=0.02), the prevalence of hypertension (92.2%vs71.4%;p=0.02) and mortality (19%vs2.9%;p=0.025) as it is showed in the table 1. When we perfom a survival analysis , it is objectified that patients with significant MR have a lower suvival but without reaching statistical significance (p=0.07) (Figure 1).
Conclusion:
The results of our study show that a significant MR clearly affects the mortality of patients with no history of ischemic heart disease who  who underwent transfemoral TAVI.

Significant MR (n=21) Non significant MR (n=69) p value
Mean age 80.5 79.94 0.9
Female/Male 81%/19% 71%/29% 0.2
LVEF (%) 53.05 60.6 0.02
Mean gradient (mmHg) 50.85 49.98 0.8
Hypertension 95.23% 71.02% 0.02
DM 28.6% 31.89% 0.8
Dyslipidemia 38.1% 49.27% 0.5
Chronic kidney disease 42.85% 57.98% 0.12
Mortality 19.05% 2.9% 0.025

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are